EFFAT ALEMZADEH1, LEILA ALLAHQOLI2, HAMIDEH DEHGHAN3, AFROOZ MAZIDIMORADI4, ALIREZA GHASEMPOUR3, HAMID SALEHINIYA5,*
Oncology Research, Vol.31, No.5, pp. 667-675, 2023, DOI:10.32604/or.2023.028406
- 21 July 2023
Abstract Liquid biopsy, including both circulating tumor cells and circulating tumor DNA, is becoming more popular as
a diagnostic tool in the clinical management of breast cancer. Elevated concentrations of these biomarkers during cancer
treatment may be used as markers for cancer progression as well as to understand the mechanisms underlying metastasis
and treatment resistance. Thus, these circulating markers serve as tools for cancer assessing and monitoring through a
simple, non-invasive blood draw. However, despite several study results currently noting a potential clinical impact of
ctDNA mutation tracking, the method is not used clinically in cancer More >
Graphic Abstract
Login
Register
